

Georg Papoutsoglou<sup>1</sup>, Matteo Cattaneo<sup>1</sup>, Adam Sciambi<sup>1</sup>, Daniel Mendoza<sup>1</sup>, Indira Krishnan<sup>1</sup>, Joanne Nguyen<sup>1</sup>, Lubna Nousheen<sup>1</sup>, Ben Geller<sup>1</sup>, Cedric Dos Santos<sup>2</sup>, Vivek S. Chopra<sup>2</sup>, Habib Hamidi<sup>2</sup>, Michael Nixon<sup>3</sup>, Yann Nouet<sup>3</sup>, Todd E. Druley<sup>1</sup> and Herve Avet-Loiseau<sup>4</sup>

<sup>1</sup>Mission Bio, 400 E Jamie Ct, Suite 101, South San Francisco, CA 94080

## Introduction

Multiple myeloma (MM) is a cancer of plasma cells with approximately 200,000 new cases/year and a 54% 5-year overall survival rate. Myeloma arises from expansion of pre-existing clonal populations, referred to as either monoclonal gammopathy of uncertain significance (MGUS) or smoldering multiple myeloma (SMM), but only ~1% of individuals with these precursors will develop fulminant MM. As myeloma cells expand, clonal genetic differences lead to relapse due to acquired resistance in nearly 100% of patients, suggesting that initial therapy is inadequate to eradicate the entire disease burden and mandating regular, long-term surveillance. Being able to more comprehensively identify low frequency subclones that may result in frank disease or resistance would enable more direct application of precision therapies. Here, we present proof of concept single cell, multi-omic data identifying the clonal populations that progress to frank myeloma or resistant disease.


## Aim

Applying single-cell proteogenomic clonal profiling of MGUS/SMM in matched diagnostic MM samples using Mission Bio's Tapestri platform and analysis tools.

## Methods

- Cryopreserved, CD138-enriched, matched SMM/MM patient samples were multiplexed in groups of 3 on the Mission Bio Tapestri platform.
- Samples were thawed and stained with a 20-plex antibody-oligo cocktail to label myeloma-specific surface markers for sequencing analysis and processed with an 846-plex DNA amplicon panel that combined whole-genome CNV coverage with MM gene hotspots.
- Single cell quantification of subclones by single nucleotide variants (SNV), copy number variants (CNV), IgH/IgK/IgL clonotyping, and surface protein expression analysis was performed.
- From an average of 3,500 cells recovered per multiplexed specimen, raw sequencing data was analyzed using Mission Bio proprietary algorithms.

## Clonal Expansion from SMM to MM




**Fig 1:** Phylogenetic trees from matched MGUS and diagnostic MM samples collected 13 months apart. In the MGUS sample, clone 2 dominated and clone 6 was only detected at 0.7%. At the time of diagnosis, clone 6 had expanded to 94%, potentially due to the combination of bi-allelic NRAS mutation, 1p loss, and 1q gain. Clones 4 and 5, which lack some of those mutations, are not as proliferative, and clone 2 had diminished to only 2.8%.

**Table 1:** The same patient as Fig 1. A detailed evaluation of disease evolution; clones from left to right, features/biomarkers top to bottom:

- (1) architecture and clonotype,
- (2) prognostic structural variants,
- (3) arm-level CNV counts,
- (4) prognostic mutations,
- (5) prognostic protein expression
- (6) clonal fraction/expansion.

## Expanded Cohort: MGUS/SMM to MM Transition



**Table 2:** 16 matched MGUS/SMM samples with the same patient's diagnostic MM sample

- Observations:**
- In 8 of 16 (50%) of cases, the dominant clone at the MGUS/SMM time point was not the dominant clone observed at diagnosis. In these cases, the average clone size at diagnosis was 11.1% (range: 0.7-28.5%).
  - Bi-allelic RAS mutations were common in expanding clones, but typically coupled with CNVs
  - Surface protein expression of immunophenotyping and therapeutic targets was variable across clones/subclones.

- Takeaways:**
- The oligoclonal variability of MGUS/SMM and fulminant MM lead to the high rate of relapse, treatment failure and mortality associated with the disease.
  - Bulk genomic measurements lack the resolution to identify these clonal differences.
  - More sensitive, single-target assays typically fail to provide therapeutic guidance.

## CONCLUSIONS

- MGUS/SMM is an oligoclonal proliferation marked by dynamic genomic and proteomic variability that can best be quantitatively characterized using single cell proteogenomics, which enables the simultaneous measurement of CDR3 clonotyping, CNVs, SNVs and surface protein expression.
- In this cohort, Tapestri identified the MGUS/SMM clone that would expand to dominance at the time of MM diagnosis with an average lead time of **15 months prior to diagnosis**.
- In addition to identifying features associated with clonal expansion, Mission Bio's Single-Cell Myeloma Multiomics Solution includes putative therapeutic targets (e.g. BCMA, RAS, CD200), which could be potentially used to guide treatment.
- Clones with bi-allelic RAS loss would **not** be expected to respond to RAS inhibition therapy (Ref 1).
- Additional studies are necessary to correlate clonal differences with therapeutic selection and patient outcomes.

## REFERENCES

1. Schavgoulidze A et al.; **"RAS/RAF landscape in monoclonal plasma cell conditions."** *Blood* 2024, Apr 21: blood.2023022295. doi: 10.1182/blood.2023022295. PMID: 38643494.
2. Sciambi A et al.; **"Single cell correlation of SNVs, CNVs and surface epitopes for clonal profiling in myeloma."** International Myeloma Society 2023 Annual Meeting, Athens, Greece (abstract).

## ACKNOWLEDGEMENTS

Thank you to Cedric Dos Santos of Genentech and Herve Avet-Loiseau of IUCT Oncopole for their generous support and guidance.

## CONTACT INFORMATION

Mission Bio, Inc., info@missionbio.com

